{
    "clinical_study": {
        "@rank": "41771", 
        "acronym": "DM+PAD", 
        "arm_group": [
            {
                "arm_group_label": "BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training", 
                "arm_group_type": "Experimental", 
                "description": "Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention."
            }, 
            {
                "arm_group_label": "BR Juice Placebo and Exercise Training", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention."
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis of this proposal is that in subjects with Type II diabetes mellitus (T2D) and\n      peripheral arterial disease (PAD) with intermittent claudication (IC), regular consumption\n      of a high nitrate supplement which raises plasma nitrite, in conjunction with 12 weeks of\n      supervised exercise training at the limb ischemic threshold (SET) will produce a greater\n      clinical benefit (increases in claudication onset time [COT] and peak walking time [PWT]\n      relative to a group with the same exercise training but supplemented with placebo .This\n      study is essentially exploratory in nature and designed to provide us with information to\n      adequately develop power and execute a larger study.  We have previously seen benefits from\n      nitrate supplementation on function in PAD."
        }, 
        "brief_title": "Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Arterial Disease and Type II Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Peripheral Arterial Disease (ABI of less than 0.9)\n\n          -  Diagnosed Type II Diabetes\n\n          -  Intermittent Claudication for 3 or more months\n\n        Exclusion Criteria:\n\n          -  Individuals with known alcohol or drug abuse problems\n\n          -  Individuals who have suffered a heart attack or stroke, or have changes on a resting\n             ECG, in the last 3 months\n\n          -  Those classified as American Heart Association Class D\n\n          -  Gangrene, impending limb loss or osteomyelitis\n\n          -  Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months\n             of enrollment\n\n          -  Severe peripheral neuropathy\n\n          -  Any condition other than PAD that limits walking\n\n          -  Chest pain during treadmill exercise which appears before the onset of claudication,\n             or >3mm ST depression during exercise\n\n          -  Subjects taking nitrates or nitroglycerin products\n\n          -  Must not be taking protein pump inhibitor medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785524", 
            "org_study_id": "Pro00039608"
        }, 
        "intervention": [
            {
                "arm_group_label": "BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training", 
                "description": "The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.", 
                "intervention_name": "Beetroot Juice (Beet-It Stamina Shot) and Exercise Training", 
                "intervention_type": "Drug", 
                "other_name": "James White Drinks"
            }, 
            {
                "arm_group_label": "BR Juice Placebo and Exercise Training", 
                "description": "The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.", 
                "intervention_name": "Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training", 
                "intervention_type": "Other", 
                "other_name": "James White Drinks"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cardiovascular Diseases", 
            "Vascular Diseases", 
            "Arterial Occlusive Diseases", 
            "Diabetes", 
            "Exercise", 
            "Functional Capacity"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "link": [
            {
                "description": "Frederick R. Cobb Non-Invasive Vascular Research Laboratory", 
                "url": "http://cardiology.medicine.duke.edu/research/clinical-research/frederick-r-cobb-non-invasive-vascular-research-laboratory"
            }, 
            {
                "description": "Duke Clinical Trials Listing", 
                "url": "http://www.dukehealth.org/clinicaltrials/20130131152500519"
            }
        ], 
        "location": {
            "contact": {
                "email": "j.d.allen@duke.edu", 
                "last_name": "Jason D Allen, PhD", 
                "phone": "919-660-6764"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke Center for Living; Wallace Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Dietary Nitrate to Augment Exercise Training Benefits in Subjects With Type II Diabetes (DM) and Peripheral Arterial Disease (PAD)", 
        "overall_contact": {
            "email": "mitch.vanbruggen@duke.edu", 
            "last_name": "Mitch D VanBruggen, M.A.", 
            "phone": "919-660-6638"
        }, 
        "overall_contact_backup": {
            "email": "katherine.ham@duke.edu", 
            "last_name": "Katherine L Ham, M.S.", 
            "phone": "919-660-6793"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Jason D Allen, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Exercise capacity will be assessed using a maximal cardiopulmonary exercise (CPX) test with expired gas analysis, for determination of peak oxygen consumption, claudication onset time and peak walking time.", 
            "measure": "Change in Exercise Capacity", 
            "safety_issue": "No", 
            "time_frame": "Baseline & 16 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785524"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University", 
            "investigator_full_name": "Jason Allen, Ph.D.", 
            "investigator_title": "Assistant Professor Doctor of Physical Therapy Program & Division of Cardiovascular Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Six-Minute Walk test. This test simple and practical assessment of functional capacity. The test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes. The test is self-paced and assesses the submaximal level of functional capacity. The subjects choose their own intensity and are allowed to stop and rest if necessary during the test.", 
                "measure": "Change in Functional Ability", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 16 Weeks"
            }, 
            {
                "description": "Ankle-brachial Index (ABI), Brachial artery flow-mediated dilation (BAFMD), calf blood flow (plethysmography), and arterial stiffness (pulse wave velocity and pulse wave reflection).", 
                "measure": "Change In Vascular Function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 16 weeks"
            }, 
            {
                "description": "Gastrocnemius muscle biopsy will be performed to measure markers of angiogenesis including; capillaries per unit area and per muscle fiber, endothelial cells with surrounding pericytes, relative fraction of type I, IIa, IIb, and IId/x fibers. If differences exist we will look for changes in cell proliferation (PCNA) and apoptosis (TUNEL); (b) oxidative capacity including; mitochondria volume with citrate synthase activity. (c) mitochondrial volume and density; (d) mitochondrial oxygen efficiency (respiratory control ratio, the ratio of ATP phosphorylation rate per oxygen consumption rate (P/O ratio), and maximal rate of ATP production). These are measurements for potential mediation analyses and gaining insight into the relative effect sizes will inform mechanistic aims in a larger trial.", 
                "measure": "Change in Angiogenesis", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 16 weeks"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}